RESUMEN
In recent years, rapid advancement in gene/protein analysis technology has resulted in target molecule identification that may be useful in cancer treatment. Therefore, "Clinical Practice Guidelines for Molecular Tumor Marker, Second Edition" was published in Japan in September 2021. These guidelines were established to align the clinical usefulness of external diagnostic products with the evaluation criteria of the Pharmaceuticals and Medical Devices Agency. The guidelines were scoped for each tumor, and a clinical questionnaire was developed based on a serious clinical problem. This guideline was based on a careful review of the evidence obtained through a literature search, and recommendations were identified following the recommended grades of the Medical Information Network Distribution Services (Minds). Therefore, this guideline can be a tool for cancer treatment in clinical practice. We have already reported the review portion of "Clinical Practice Guidelines for Molecular Tumor Marker, Second Edition" as Part 1. Here, we present the English version of each part of the Clinical Practice Guidelines for Molecular Tumor Marker, Second Edition.
Asunto(s)
Biomarcadores de Tumor , Neoplasias , Humanos , Biomarcadores de Tumor/genética , Biomarcadores de Tumor/análisis , Japón , Neoplasias/terapia , Neoplasias/genética , Neoplasias/diagnósticoAsunto(s)
Azacitidina/uso terapéutico , Síndromes Mielodisplásicos/complicaciones , Síndromes Mielodisplásicos/tratamiento farmacológico , Protoporfiria Eritropoyética/diagnóstico , Protoporfiria Eritropoyética/etiología , beta Caroteno/uso terapéutico , Anciano , Benzoatos/uso terapéutico , Deferasirox , Humanos , Masculino , Protoporfiria Eritropoyética/tratamiento farmacológico , Triazoles/uso terapéuticoRESUMEN
A 24-year-old woman with chronic myeloid leukemia (CML) chronic phase was started on imatinib in August 2004 and complete hematologic response (CHR) was achieved. In May 2006, controlled ovarian hyperstimulation was started after stopping imatinib. Her pregnancy test was positive in October 2006. At 32 weeks, she had 29% metaphases positive for the Ph chromosome; CHR was sustained. She had a normal delivery at 38 weeks without any complications. Five weeks after delivery, imatinib was resumed. Complete molecular response was sustained 5 months after re-administration of imatinib. A CML patient may give a birth after intentionally stopping imatinib before conception.